Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 3/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14813926 | 0.88 | KDM4E (0.41) | HCAR2SCN1ASCN2ASCN3ALMNA | |
| SCHEMBL6267445 | 0.83 | HCAR2 (0.43) | HCAR2SCN1ASCN2ASCN3ALMNA | |
| SCHEMBL2701953 | 0.81 | HTT (0.42) | SCN1ASCN2ASCN3ALMNAHTT | |
| SCHEMBL431888 | 0.81 | SCN1A (0.41) | HCAR2SCN1ASCN2ASCN3ALMNA | |
| SCHEMBL9871371 | 0.79 | TAAR1 (0.43) | SCN1ASCN2ASCN3ALMNAHTT | |
| SCHEMBL19368242 | 0.79 | HPGD (0.41) | HCAR2SCN1ASCN2ASCN3ALMNA | |
| SCHEMBL17305906 | 0.79 | SLC6A2 (0.46) | SCN1ASCN2ASCN3ALMNAHTT | |
| SCHEMBL97127 | 0.79 | TRPA1 (0.44) | HCAR2SCN1ASCN2ASCN3ALMNA | |
| SCHEMBL29633537 | 0.79 | TRPA1 (0.44) | HCAR2SCN1ASCN2ASCN3ALMNA | |
| SCHEMBL584471 | 0.79 | ADRA2A (0.42) | SCN1ASCN2ASCN3ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20200317644-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2020-10-08 | — | — | US | disclosed |
| EP-3524599-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2019-08-14 | — | — | EP | disclosed |
| US-20180346449-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2018-12-06 | — | — | US | disclosed |
| EP-3199533-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2017-08-02 | — | — | EP | disclosed |
| EP-3097095-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | AbbVie Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| WO-2015112754-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | ABBVIE INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| US-20150183763-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2015-07-02 | — | — | US | disclosed |
| EP-2784074-A1 | PYRAZOLE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Japan Tobacco, Inc. (JP) | 2014-10-01 | — | — | EP | disclosed |
| US-8846746-B2 | Pyrazole compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2014-09-30 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
| EP-1000620-B1 | Lp(a)-LOWERING AGENTS AND APOPROTEIN (a) PRODUCTION INHIBITORS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-6166036-A | Lp(a)-lowering agent and apolipoprotein (a) formation suppressing agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-1000620-A1 | Lp(a)-LOWERING AGENTS AND APOPROTEIN (a) PRODUCTION INHIBTORS | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-05-17 | — | — | EP | disclosed |
| EP-0393607-B1 | Phenylcarboxylic acid derivatives having a hetero ring | OTSUKA PHARMA CO LTD (JP) | 1996-02-21 | — | — | EP | disclosed |
| US-5145865-A | Fatty acid, cholesterol synthesis inhibitors; enzyme inhibitors; antilipemic agents | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1992-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346449-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP3A7, CYP3A5 | HCAR2 4076/4885SCN1A 510/4885SCN2A 734/4885 |
| US-20230348438-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP3A7, CYP3A5 | HCAR2 4076/4885SCN1A 510/4885SCN2A 734/4885 |
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | HCAR2 3078/4885SCN1A 2083/4885SCN2A 2170/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | HCAR2 2804/4885SCN1A 3959/4885SCN2A 4436/4885 |
| US-20200317644-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP3A7, CYP3A5 | HCAR2 4076/4885SCN1A 510/4885SCN2A 734/4885 |
| US-20150183763-A1 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | SLC5A1, SLC5A2, SLC34A1 | HCAR2 1836/4885SCN1A 545/4885SCN2A 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.